Division of Nephrology, Toronto General Hospital, University of Toronto, Ontario, Canada.
Kidney Int. 2011 Aug;80(3):310-7. doi: 10.1038/ki.2011.126. Epub 2011 May 4.
The Oxford classification of IgA nephropathy (IgAN) identified four pathological elements that were of prognostic value and additive to known clinical and laboratory variables in predicting patient outcome. These features are segmental glomerulosclerosis/adhesion, mesangial hypercellularity, endocapillary proliferation, and tubular atrophy/interstitial fibrosis. Here, we tested the Oxford results using an independent cohort of 187 adults and children with IgAN from 4 centers in North America by comparing the performance of the logistic regression model and the predictive value of each of the four lesions in both data sets. The cohorts had similar clinical and histological findings, presentations, and clinicopathological correlations. During follow-up, however, the North American cohort received more immunosuppressive and antihypertensive therapies. Identifying patients with a rapid decline in the rate of renal function using the logistic model from the original study in the validation data set was good (c-statistic 0.75), although less precise than in the original study (0.82). Individually, each pathological variable offered the same predictive value in both cohorts except mesangial hypercellularity, which was a weaker predictor. Thus, this North American cohort validated the Oxford IgAN classification and supports its utilization. Further studies are needed to determine the relationship to the impact of treatment and to define the value of the mesangial hypercellularity score.
牛津 IgA 肾病(IgAN)分类法确定了四个具有预后价值的病理特征,这些特征与已知的临床和实验室变量相加,可预测患者的预后。这些特征是节段性肾小球硬化/粘连、系膜细胞增生、毛细血管内增生和肾小管萎缩/间质纤维化。在这里,我们通过比较逻辑回归模型的性能以及在两个数据集的每个病变的预测值,使用来自北美 4 个中心的 187 名成人和儿童 IgAN 的独立队列对牛津结果进行了测试。这些队列具有相似的临床和组织学表现、表现和临床病理相关性。然而,在随访期间,北美队列接受了更多的免疫抑制和降压治疗。在验证数据集中,使用原始研究中的逻辑模型识别肾功能快速下降的患者的效果良好(C 统计量为 0.75),尽管不如原始研究准确(0.82)。在两个队列中,每个病理变量的预测价值都相同,除了系膜细胞增生,它是一个较弱的预测因素。因此,这个北美的队列验证了牛津 IgAN 分类,并支持其应用。需要进一步的研究来确定与治疗效果的关系,并定义系膜细胞增生评分的价值。